

Carsten Bokemeyer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/512764/publications.pdf>

Version: 2024-02-01

219
papers

6,457
citations

136950

32
h-index

85541

71
g-index

222
all docs

222
docs citations

222
times ranked

12985
citing authors

#	ARTICLE	IF	CITATIONS
1	Autopsy Findings and Venous Thromboembolism in Patients With COVID-19. <i>Annals of Internal Medicine</i> , 2020, 173, 268-277.	3.9	1,954
2	Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials. <i>European Journal of Cancer</i> , 2012, 48, 1466-1475.	2.8	506
3	Quality of life, psychological burden, needs, and satisfaction during specialized inpatient palliative care in family caregivers of advanced cancer patients. <i>BMC Palliative Care</i> , 2017, 16, 31.	1.8	122
4	The polyphosphate factor XII pathway drives coagulation in prostate cancer-associated thrombosis. <i>Blood</i> , 2015, 126, 1379-1389.	1.4	117
5	High Ki67 expression is an independent good prognostic marker in colorectal cancer. <i>Journal of Clinical Pathology</i> , 2016, 69, 209-214.	2.0	114
6	Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitors. <i>Cancers</i> , 2019, 11, 835.	3.7	109
7	Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium. <i>Journal of Clinical Oncology</i> , 2021, 39, 1563-1574.	1.6	108
8	Heterogeneity of amplification of HER2, EGFR, CCND1 and MYC in gastric cancer. <i>BMC Gastroenterology</i> , 2015, 15, 7.	2.0	101
9	Expression of Hedgehog Pathway Mediator <i>GLI1</i> Represents a Negative Prognostic Marker in Human Acute Myeloid Leukemia and Its Inhibition Exerts Antileukemic Effects. <i>Clinical Cancer Research</i> , 2015, 21, 2388-2398.	7.0	88
10	Blockade of Myeloid-Derived Suppressor Cell Expansion with All- <i>Trans</i> Retinoic Acid Increases the Efficacy of Antiangiogenic Therapy. <i>Cancer Research</i> , 2018, 78, 3220-3232.	0.9	84
11	Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium. <i>Journal of Clinical Oncology</i> , 2021, 39, 1553-1562.	1.6	83
12	Anxiety and fear of cancer recurrence and its association with supportive care needs and health-care service utilization in cancer patients. <i>Journal of Cancer Survivorship</i> , 2015, 9, 567-575.	2.9	74
13	Cetuximab Resistance in Head and Neck Cancer Is Mediated by EGFR-K521 Polymorphism. <i>Cancer Research</i> , 2017, 77, 1188-1199.	0.9	71
14	Immune checkpoints PVR and PVRL2 are prognostic markers in AML and their blockade represents a new therapeutic option. <i>Oncogene</i> , 2018, 37, 5269-5280.	5.9	65
15	Marine alkaloid Monanchocidin a overcomes drug resistance by induction of autophagy and lysosomal membrane permeabilization. <i>Oncotarget</i> , 2015, 6, 17328-17341.	1.8	61
16	Epidermal growth factor receptor mutation mediates cross-resistance to panitumumab and cetuximab in gastrointestinal cancer. <i>Oncotarget</i> , 2015, 6, 12035-12047.	1.8	60
17	The marine triterpene glycoside frondoside <i>A</i> exhibits activity <i>in vitro</i> and <i>in vivo</i> in prostate cancer. <i>International Journal of Cancer</i> , 2016, 138, 2450-2465.	5.1	60
18	Targeting the TIGIT-PVR immune checkpoint axis as novel therapeutic option in breast cancer. <i>Onc Immunology</i> , 2019, 8, e1674605.	4.6	59

#	ARTICLE	IF	CITATIONS
19	Psychological burden in family caregivers of patients with advanced cancer at initiation of specialist inpatient palliative care. <i>BMC Palliative Care</i> , 2019, 18, 102.	1.8	59
20	Peritumoral eosinophils predict recurrence in colorectal cancer. <i>Modern Pathology</i> , 2015, 28, 403-413.	5.5	56
21	Late adverse effects and quality of life in survivors of testicular germ cell tumour. <i>Nature Reviews Urology</i> , 2021, 18, 227-245.	3.8	49
22	Guanidine Alkaloids from the Marine Sponge <i>Monanchora pulchra</i> Show Cytotoxic Properties and Prevent EGF-Induced Neoplastic Transformation in Vitro. <i>Marine Drugs</i> , 2016, 14, 133.	4.6	48
23	Long-term CD38 saturation by daratumumab interferes with diagnostic myeloma cell detection. <i>Haematologica</i> , 2017, 102, e368-e370.	3.5	48
24	Activity of aaptamine and two derivatives, demethyloxyaaptamine and isoaaptamine, in cisplatin-resistant germ cell cancer. <i>Journal of Proteomics</i> , 2014, 96, 223-239.	2.4	43
25	The marine triterpene glycoside frondoside A induces p53-independent apoptosis and inhibits autophagy in urothelial carcinoma cells. <i>BMC Cancer</i> , 2017, 17, 93.	2.6	42
26	T-cell diversification reflects antigen selection in the blood of patients on immune checkpoint inhibition and may be exploited as liquid biopsy biomarker. <i>International Journal of Cancer</i> , 2017, 140, 2535-2544.	5.1	42
27	Prevalence and Predictors of Distress, Anxiety, Depression, and Quality of Life in Bereaved Family Caregivers of Patients With Advanced Cancer. <i>American Journal of Hospice and Palliative Medicine</i> , 2020, 37, 201-213.	1.4	42
28	Pretrichodermamides Dâ€“F from a Marine Algicolous Fungus <i>Penicillium</i> sp. KMM 4672. <i>Marine Drugs</i> , 2016, 14, 122.	4.6	41
29	Treatment outcome according to tumor RAS mutation status in OPUS study patients with metastatic colorectal cancer (mCRC) randomized to FOLFOX4 with/without cetuximab.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3505-3505.	1.6	41
30	Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer (MCRC): Final results of the phase II AVETUX trial (AIO-KRK-0216).. <i>Journal of Clinical Oncology</i> , 2020, 38, 96-96.	1.6	41
31	Aaptamines from the Marine Sponge <i>Aaptos</i> sp. Display Anticancer Activities in Human Cancer Cell Lines and Modulate AP-1-, NF- κ B-, and p53-Dependent Transcriptional Activity in Mouse JB6 Cl41 Cells. <i>BioMed Research International</i> , 2014, 2014, 1-7.	1.9	39
32	Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitorâ€“Sensitive and -Resistant Chronic Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2017, 23, 2289-2300.	7.0	38
33	Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trial. <i>Leukemia</i> , 2022, 36, 885-888.	7.2	38
34	Successful Targeting of the Warburg Effect in Prostate Cancer by Glucose-Conjugated 1,4-Naphthoquinones. <i>Cancers</i> , 2019, 11, 1690.	3.7	34
35	Cyclin D1 gene amplification is highly homogeneous in breast cancer. <i>Breast Cancer</i> , 2016, 23, 111-119.	2.9	33
36	Therapeutic approaches for refractory germ cell cancer. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 389-397.	2.4	33

#	ARTICLE	IF	CITATIONS
37	Epidermal growth factor receptor (EGFR) in salivary gland carcinomas: Potentials as therapeutic target. <i>Oral Oncology</i> , 2012, 48, 991-996.	1.5	31
38	Quinone-carbohydrate nonglucoside conjugates as a new type of cytotoxic agents: Synthesis and determination of in vitro activity. <i>European Journal of Medicinal Chemistry</i> , 2014, 77, 139-144.	5.5	31
39	BCL2-overexpressing prostate cancer cells rely on PARP1-dependent end-joining and are sensitive to combined PARP inhibitor and radiation therapy. <i>Cancer Letters</i> , 2018, 423, 60-70.	7.2	31
40	Exploratory analysis of the neutrophil to lymphocyte ratio in patients with pulmonary arterial hypertension. <i>BMC Pulmonary Medicine</i> , 2017, 17, 72.	2.0	30
41	PD-L1 targeting and subclonal immune escape mediated by PD-L1 mutations in metastatic colorectal cancer. <i>Journal of Clinical Oncology</i> , 2021, 9, e002844.		29
42	Cyclooxygenase-2 blockade can improve efficacy of VEGF-targeting drugs. <i>Oncotarget</i> , 2015, 6, 6341-6358.	1.8	28
43	Supportive care needs and service use during palliative care in family caregivers of patients with advanced cancer: a prospective longitudinal study. <i>Supportive Care in Cancer</i> , 2021, 29, 1303-1315.	2.2	28
44	Combined inhibition of GLI and FLT3 signaling leads to effective anti-leukemic effects in human acute myeloid leukemia. <i>Oncotarget</i> , 2017, 8, 29187-29201.	1.8	28
45	Nanobody Targeting of Epidermal Growth Factor Receptor (EGFR) Ectodomain Variants Overcomes Resistance to Therapeutic EGFR Antibodies. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 823-833.	4.1	27
46	Comparison of three different serum-free light-chain assays—implications on diagnostic and therapeutic monitoring of multiple myeloma. <i>Blood Cancer Journal</i> , 2020, 10, 2.	6.2	27
47	Post-Vaccination Anti-SARS-CoV-2-Antibody Response in Patients with Multiple Myeloma Correlates with Low CD19+ B-Lymphocyte Count and Anti-CD38 Treatment. <i>Cancers</i> , 2021, 13, 3800.	3.7	27
48	Denosumab mimics the natural decoy receptor osteoprotegerin by interacting with its major binding site on RANKL. <i>Oncotarget</i> , 2014, 5, 6647-6653.	1.8	27
49	Combined Blockade of TIGIT and CD39 or A2AR Enhances NK-92 Cell-Mediated Cytotoxicity in AML. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12919.	4.1	27
50	The effects of music therapy in patients with high-dose chemotherapy and stem cell support: a randomized pilot study. <i>Psycho-Oncology</i> , 2017, 26, 377-384.	2.3	26
51	Fronodoside A induces AIF-associated caspase-independent apoptosis in Burkitt lymphoma cells. <i>Leukemia and Lymphoma</i> , 2017, 58, 2905-2915.	1.3	26
52	Retinal toxicity after cisplatin-based chemotherapy in patients with germ cell cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 1319-1325.	2.5	26
53	Impact of taste and smell training on taste disorders during chemotherapy—TASTE trial. <i>Cancer Management and Research</i> , 2019, Volume 11, 4493-4504.	1.9	26
54	Effect of KRAS and NRAS mutations on treatment outcomes in patients with metastatic colorectal cancer (mCRC) treated first-line with cetuximab plus FOLFOX4: New results from the OPUS study. <i>Journal of Clinical Oncology</i> , 2014, 32, LBA444-LBA444.	1.6	26

#	ARTICLE	IF	CITATIONS
55	Cdc7 overexpression is an independent prognostic marker and a potential therapeutic target in colorectal cancer. <i>Diagnostic Pathology</i> , 2015, 10, 125.	2.0	25
56	Investigational targeted therapies for the treatment of testicular germ cell tumors. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 1033-1043.	4.1	25
57	Efficacy and safety of gemcitabine, oxaliplatin, and paclitaxel in cisplatin-refractory germ cell cancer in routine care Registry data from an outcomes research project of the German Testicular Cancer Study Group. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 168.e21-168.e28.	1.6	25
58	Platinum-refractory germ cell tumors: an update on current treatment options and developments. <i>World Journal of Urology</i> , 2017, 35, 1167-1175.	2.2	25
59	Evaluation of a program for routine implementation of shared decision-making in cancer care: study protocol of a stepped wedge cluster randomized trial. <i>Implementation Science</i> , 2018, 13, 51.	6.9	25
60	Everolimus in patients with multiply relapsed or cisplatin refractory germ cell tumors: results of a phase II, single-arm, open-label multicenter trial (RADIT) of the German Testicular Cancer Study Group. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 717-723.	2.5	25
61	BET-inhibition by JQ1 promotes proliferation and self-renewal capacity of hematopoietic stem cells. <i>Haematologica</i> , 2018, 103, 939-948.	3.5	23
62	Inspired by Sea Urchins: Warburg Effect Mediated Selectivity of Novel Synthetic Non-Glycoside 1,4-Naphthoquinone-6S-Glucose Conjugates in Prostate Cancer. <i>Marine Drugs</i> , 2020, 18, 251.	4.6	23
63	Conceptual framework for precision cancer medicine in Germany: Consensus statement of the Deutsche Krebshilfe working group Molecular Diagnostics and Therapy. <i>European Journal of Cancer</i> , 2020, 135, 1-7.	2.8	23
64	Polyphenolic Compounds from <i>Lespedeza Bicolor</i> Root Bark Inhibit Progression of Human Prostate Cancer Cells via Induction of Apoptosis and Cell Cycle Arrest. <i>Biomolecules</i> , 2020, 10, 451.	4.0	23
65	Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO) Tj ETQq1 1 0.7843142gBT /Over	0.7843142	23
66	The trifunctional antibody catumaxomab amplifies and shapes tumor-specific immunity when applied to gastric cancer patients in the adjuvant setting. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 2533-2542.	3.3	21
67	The P2-receptor-mediated Ca ²⁺ signalosome of the human pulmonary endothelium - implications for pulmonary arterial hypertension. <i>Purinergic Signalling</i> , 2019, 15, 299-311.	2.2	21
68	Depth of response to isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: Interim analysis of the GMMG-CONCEPT trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 8508-8508.	1.6	21
69	Bone Marrow-Resident V β 1 T Cells Co-express TIGIT With PD-1, TIM-3 or CD39 in AML and Myeloma. <i>Frontiers in Medicine</i> , 2021, 8, 763773.	2.6	21
70	Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer (MCRC): Results of the safety run-in phase of the phase II AVETUX trial (AIO-KRK-0216). <i>Journal of Clinical Oncology</i> , 2018, 36, 3561-3561.	1.6	20
71	The Preference to Discuss Expected Survival Is Associated with Loss of Meaning and Purpose in Terminally Ill Cancer Patients. <i>Journal of Palliative Medicine</i> , 2015, 18, 970-976.	1.1	19
72	Loss of H2Bub1 Expression is Linked to Poor Prognosis in Nodal Negative Colorectal Cancers. <i>Pathology and Oncology Research</i> , 2016, 22, 95-102.	1.9	19

#	ARTICLE	IF	CITATIONS
73	Palliative treatment of germ cell cancer. <i>Cancer Treatment Reviews</i> , 2018, 71, 102-107.	7.7	19
74	Ethical challenges in family caregivers of patients with advanced cancer – a qualitative study. <i>BMC Palliative Care</i> , 2020, 19, 70.	1.8	19
75	Tissue-Specific Expression of TIGIT, PD-1, TIM-3, and CD39 by T Cells in Ovarian Cancer. <i>Cells</i> , 2022, 11, 964.	4.1	19
76	Acute effects of exercise on the inflammatory state in patients with idiopathic pulmonary arterial hypertension. <i>BMC Pulmonary Medicine</i> , 2016, 16, 145.	2.0	18
77	Symptom burden in long-term germ cell tumor survivors. <i>Supportive Care in Cancer</i> , 2016, 24, 2243-2250.	2.2	18
78	Identification of a High-Level MET Amplification in CTCs and ctDNA of an ALK-Positive NSCLC Patient Developing Evasive Resistance to Crizotinib. <i>Journal of Thoracic Oncology</i> , 2018, 13, e243-e246.	1.1	18
79	The Impact of Smoking Cessation and Continuation on Recurrence and Survival in Patients with Head and Neck Cancer: A Systematic Review of the Literature. <i>Oncology Research and Treatment</i> , 2020, 43, 549-558.	1.2	18
80	Phase III study of nivolumab alone or combined with ipilimumab as immunotherapy versus standard of care in resectable head and neck squamous cell carcinoma. <i>Future Oncology</i> , 2020, 16, 3035-3043.	2.4	18
81	Urupocidin C: a new marine guanidine alkaloid which selectively kills prostate cancer cells via mitochondria targeting. <i>Scientific Reports</i> , 2020, 10, 9764.	3.3	18
82	Subcellular Compartmentalization of Survivin is Associated with Biological Aggressiveness and Prognosis in Prostate Cancer. <i>Scientific Reports</i> , 2020, 10, 3250.	3.3	18
83	The Role of Relative Lymphocyte Count as a Biomarker for the Effect of Catumaxomab on Survival in Malignant Ascites Patients: Results from a Phase II/III Study. <i>Clinical Cancer Research</i> , 2014, 20, 3348-3357.	7.0	17
84	Anti-migratory activity of marine alkaloid monanchocidin A – proteomics-based discovery and confirmation. <i>Proteomics</i> , 2016, 16, 1590-1603.	2.2	17
85	Exploring the gender dimension of problems and needs of patients receiving specialist palliative care in a German palliative care unit - the perspectives of patients and healthcare professionals. <i>BMC Palliative Care</i> , 2019, 18, 59.	1.8	17
86	<i>BRAF</i> V600E Mutation in First-Line Metastatic Colorectal Cancer: An Analysis of Individual Patient Data From the ARCAD Database. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1386-1395.	6.3	17
87	The developmental origin of cancers defines basic principles of cisplatin resistance. <i>Cancer Letters</i> , 2021, 519, 199-210.	7.2	17
88	A phase II study of catumaxomab administered intra- and postoperatively as part of a multimodal approach in primarily resectable gastric cancer. <i>Gastric Cancer</i> , 2015, 18, 833-42.	5.3	16
89	Comprehensive cytogenetic and molecular cytogenetic analysis of 44 Burkitt lymphoma cell lines: Secondary chromosomal changes characterization, karyotypic evolution, and comparison with primary samples. <i>Genes Chromosomes and Cancer</i> , 2014, 53, 497-515.	2.8	16
90	Prospective Study on Music Therapy in Terminally Ill Cancer Patients during Specialized Inpatient Palliative Care. <i>Journal of Palliative Medicine</i> , 2016, 19, 394-399.	1.1	16

#	ARTICLE	IF	CITATIONS
91	Marine compound rhizochalinin shows high <i>in vitro</i> and <i>in vivo</i> efficacy in castration resistant prostate cancer. <i>Oncotarget</i> , 2016, 7, 69703-69717.	1.8	16
92	Downregulation of GLI3 Expression Mediates Chemotherapy Resistance in Acute Myeloid Leukemia. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5084.	4.1	15
93	Immune Thrombocytopenic Purpura after vaccination with COVID-19 Vaccine (ChAdOx1 nCov-19). <i>Blood</i> , 2021, 138, 996-999.	1.4	15
94	Synthesis and anticancer activity of the derivatives of marine compound rhizochalin in castration resistant prostate cancer. <i>Oncotarget</i> , 2018, 9, 16962-16973.	1.8	15
95	The zinc-finger transcription factor SALL4 is frequently expressed in human cancers: association with clinical outcome in squamous cell carcinoma but not in adenocarcinoma of the esophagus. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016, 468, 483-492.	2.8	14
96	Fatal Myelotoxicity Following Palliative Chemotherapy With Cisplatin and Gemcitabine in a Patient With Stage IV Cholangiocarcinoma Linked to Post Mortem Diagnosis of Fanconi Anemia. <i>Frontiers in Oncology</i> , 2019, 9, 420.	2.8	14
97	Challenges Faced by Prehospital Emergency Physicians Providing Emergency Care to Patients with Advanced Incurable Diseases. <i>Emergency Medicine International</i> , 2019, 2019, 1-11.	0.8	14
98	Efficacy and Mechanism of Action of Marine Alkaloid 3,10-Dibromofascaplysin in Drug-Resistant Prostate Cancer Cells. <i>Marine Drugs</i> , 2020, 18, 609.	4.6	14
99	A Phase II study of selinexor plus cytarabine and idarubicin in patients with relapsed/refractory acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2020, 190, e169-e173.	2.5	14
100	N-Terminal Pro-Brain Natriuretic Peptide Is a Useful Prognostic Marker in Patients with Pre-Capillary Pulmonary Hypertension and Renal Insufficiency. <i>PLoS ONE</i> , 2014, 9, e94263.	2.5	14
101	Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: Pooled analysis of 2879 patients from AGITC (MAX), COIN, FOCUS2, OPUS, CRYSTAL and COIN-B trials in the ARCAD database. <i>European Journal of Cancer</i> , 2018, 103, 205-213.	2.8	13
102	Evaluation of a program for routine implementation of shared decision-making in cancer care: results of a stepped wedge cluster randomized trial. <i>Implementation Science</i> , 2021, 16, 106.	6.9	13
103	Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trial. <i>International Journal of Cancer</i> , 2019, 145, 857-868.	5.1	12
104	Prognostic and Predictive Impact of Primary Tumor Sidedness for Previously Untreated Advanced Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1705-1713.	6.3	12
105	Second-Generation Antiandrogen Therapy Radiosensitizes Prostate Cancer Regardless of Castration State through Inhibition of DNA Double Strand Break Repair. <i>Cancers</i> , 2020, 12, 2467.	3.7	11
106	Systematic symptom and problem assessment at admission to the palliative care ward – perspectives and prognostic impacts. <i>BMC Palliative Care</i> , 2020, 19, 75.	1.8	11
107	Implementation analysis of patient reported outcomes (PROs) in oncological routine care: an observational study protocol. <i>Health and Quality of Life Outcomes</i> , 2020, 18, 3.	2.4	11
108	Thoughts of death and suicidality among patients with cancer: Examining subtypes and their association with mental disorders. <i>Psycho-Oncology</i> , 2021, 30, 2023-2031.	2.3	11

#	ARTICLE	IF	CITATIONS
109	Current Treatment Approaches to Newly Diagnosed Multiple Myeloma. <i>Oncology Research and Treatment</i> , 2021, 44, 690-699.	1.2	11
110	Immunotherapy in Advanced Prostate Cancerâ€”Light at the End of the Tunnel?. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2569.	4.1	11
111	Cabazitaxel overcomes cisplatin resistance in germ cell tumour cells. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 1979-1994.	2.5	10
112	Dynamic changes of the normal B lymphocyte repertoire in CLL in response to ibrutinib or FCR chemo-immunotherapy. <i>Oncolmmunology</i> , 2018, 7, e1417720.	4.6	10
113	Intermediate prognosis in metastatic germ cell tumoursâ€”outcome and prognostic factors. <i>European Journal of Cancer</i> , 2018, 94, 16-25.	2.8	10
114	The prognostic impact of different tumor marker levels in nonseminomatous germ cell tumor patients with intermediate prognosis: A registry of the International Global Germ Cell Tumor Collaborative Group (G3). <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 809.e19-809.e25.	1.6	10
115	The Actin Binding Protein Plastin-3 Is Involved in the Pathogenesis of Acute Myeloid Leukemia. <i>Cancers</i> , 2019, 11, 1663.	3.7	10
116	Detection of doxorubicin, cisplatin and therapeutic antibodies in formalin-fixed paraffin-embedded human cancer cells. <i>Histochemistry and Cell Biology</i> , 2020, 153, 367-377.	1.7	10
117	Marine alkaloid monanchoxymycalin C: a new specific activator of JNK1/2 kinase with anticancer properties. <i>Scientific Reports</i> , 2020, 10, 13178.	3.3	10
118	Existential distress in patients with advanced cancer and their caregivers: study protocol of a longitudinal cohort study. <i>BMJ Open</i> , 2021, 11, e046351.	1.9	10
119	Deoxycytidine kinase is downregulated under hypoxic conditions and confers resistance against cytarabine in acute myeloid leukaemia. <i>European Journal of Haematology</i> , 2016, 97, 239-244.	2.2	9
120	New Trisulfated Steroids from the Vietnamese Marine Sponge <i>Halichondria vansoesti</i> and Their PSA Expression and Glucose Uptake Inhibitory Activities. <i>Marine Drugs</i> , 2019, 17, 445.	4.6	9
121	Effects of a structured counselling-based intervention to improve physical activity behaviour of adolescents and young adult cancer survivors â€” the randomized phase II Motivate AYA â€” MAYA trial. <i>Clinical Rehabilitation</i> , 2021, 35, 1164-1174.	2.2	9
122	Clinical efficacy and safety of regorafenib (REG) in the treatment of metastatic colorectal cancer (mCRC) in daily practice in Germany: Final results of the prospective multicentre non-interventional RECORA study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 748-748.	1.6	9
123	Study of Structureâ€”Activity Relationships of the Marine Alkaloid Fascaplysin and Its Derivatives as Potent Anticancer Agents. <i>Marine Drugs</i> , 2022, 20, 185.	4.6	9
124	Severe and irreversible myelopathy after concurrent systemic and intrathecal nucleoside analogue treatment for refractory diffuse large B-cell lymphoma: A case report and review of the literature. <i>Journal of Oncology Pharmacy Practice</i> , 2016, 22, 523-527.	0.9	8
125	Proteomicâ€”based investigations on the mode of action of the marine anticancer compound rhizochalinin. <i>Proteomics</i> , 2017, 17, 1700048.	2.2	8
126	Human chorionic gonadotropinâ€”positive seminoma patients: A registry compiled by the global germ cell tumor collaborative group (G3). <i>European Journal of Cancer</i> , 2020, 132, 127-135.	2.8	8

#	ARTICLE	IF	CITATIONS
127	Selinexor (KPT-330), an Oral Selective Inhibitor of Nuclear Export (SINE) Compound, in Combination with FOLFOX in Patients with Metastatic Colorectal Cancer (mCRC) - Final Results of the Phase I Trial SENTINEL. <i>Current Cancer Drug Targets</i> , 2020, 20, 811-817.	1.6	8
128	A transplant "immunome" screening platform defines a targetable epitope fingerprint of multiple myeloma. <i>Blood</i> , 2016, 127, 3202-3214.	1.4	7
129	Hodgkin's lymphoma as a rare variant of Richter's transformation in chronic lymphocytic leukemia: A case report and review of the literature. <i>Molecular and Clinical Oncology</i> , 2016, 4, 390-392.	1.0	7
130	Treatment approach in patients with hyperbilirubinemia secondary to liver metastases in gastrointestinal malignancies: a case series and review of literature. <i>Therapeutic Advances in Medical Oncology</i> , 2016, 8, 144-152.	3.2	7
131	A significant proportion of patients with primary central nervous system lymphoma harbor clonal bone marrow B-cells. <i>Leukemia and Lymphoma</i> , 2019, 60, 334-340.	1.3	7
132	Prevalence of definite antiphospholipid syndrome in carriers of the JAK2V617F mutation. <i>Thrombosis Research</i> , 2021, 198, 55-61.	1.7	7
133	Risk factors for poor humoral response to primary and booster SARS-CoV-2 vaccination in hematologic and oncological outpatients" COVIDOUT study. <i>Cancer Cell</i> , 2022, 40, 581-583.	16.8	7
134	How to classify, diagnose, treat and follow-up extragonadal germ cell tumors? A systematic review of available evidence. <i>World Journal of Urology</i> , 2022, 40, 2863-2878.	2.2	7
135	Impact, challenges and limits of inpatient palliative care consultations " perspectives of requesting and conducting physicians. <i>BMC Health Services Research</i> , 2020, 20, 86.	2.2	6
136	Development and preliminary psychometric investigation of the German Satisfaction with Comprehensive Cancer Care (SCCC) Questionnaire. <i>Health and Quality of Life Outcomes</i> , 2021, 19, 147.	2.4	6
137	Activity of New Synthetic (2-Chloroethylthio)-1,4-naphthoquinones in Prostate Cancer Cells. <i>Pharmaceuticals</i> , 2021, 14, 949.	3.8	6
138	Mebendazole Mediates Proteasomal Degradation of Gli Transcription Factors in Acute Myeloid Leukemia. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10670.	4.1	6
139	Non-Random Pattern of Integration for Epstein-Barr Virus with Preference for Gene-Poor Genomic Chromosomal Regions into the Genome of Burkitt Lymphoma Cell Lines. <i>Viruses</i> , 2022, 14, 86.	3.3	6
140	Efficacy of anti-epidermal growth factor receptor agents in patients with RAS wild-type metastatic colorectal cancer " 70 years. <i>European Journal of Cancer</i> , 2022, 163, 1-15.	2.8	6
141	Adding cetuximab to paclitaxel and carboplatin for first-line treatment of carcinoma of unknown primary (CUP): results of the Phase 2 AIO trial PACET-CUP. <i>British Journal of Cancer</i> , 2021, 124, 721-727.	6.4	5
142	Outcome of a Real-World Patient Cohort with Secondary CNS Lymphoma Treated with High-Intensity Chemoimmunotherapy and Autologous Stem Cell Transplantation. <i>Oncology Research and Treatment</i> , 2021, 44, 375-381.	1.2	5
143	Lorlatinib Induces Durable Disease Stabilization in a Pancreatic Cancer Patient with a <i>ROS1</i> p.L1950F Mutation: Case Report. <i>Oncology Research and Treatment</i> , 2021, 44, 495-502.	1.2	5
144	The prognostic impact of the smoking status of cancer patients receiving systemic treatment, radiation therapy, and surgery: A systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2022, 172, 130-137.	2.8	5

#	ARTICLE	IF	CITATIONS
145	Effect of myeloperoxidase on the anticoagulant activity of low molecular weight heparin and rivaroxaban in an in vitro tumor model. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 3267-3279.	3.8	4
146	The prognostic significance of lactate dehydrogenase levels in seminoma patients with advanced disease: an analysis by the Global Germ Cell Tumor Collaborative Group (G3). <i>World Journal of Urology</i> , 2021, 39, 3407-3414.	2.2	4
147	How does spirituality manifest in family caregivers of terminally ill cancer patients? A qualitative secondary analysis. <i>Palliative and Supportive Care</i> , 2022, 20, 45-54.	1.0	4
148	Changes in items of a comprehensive geriatric assessment (CGA) during follow-up: Results from the IN-GHO registry.. <i>Journal of Clinical Oncology</i> , 2014, 32, 9547-9547.	1.6	4
149	Rectal versus left-sided colon cancers: Clinicopathological differences observed in a pooled analysis of 4,182 patients enrolled to 8 clinical trials from the ARCAD database.. <i>Journal of Clinical Oncology</i> , 2017, 35, 675-675.	1.6	4
150	Prognostic impact of LDH and HCG levels in marker-positive seminomas.. <i>Journal of Clinical Oncology</i> , 2020, 38, 392-392.	1.6	4
151	COVID-19 and seasonal influenza: a comparative analysis in patients with hematological malignancies. <i>Leukemia and Lymphoma</i> , 2022, 63, 664-671.	1.3	4
152	Comparison of acetylsalicylic acid and clopidogrel non-responsiveness assessed by light transmittance aggregometry and PFA-100 [®] in patients undergoing neuroendovascular procedures. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, 383-392.	2.3	4
153	Evaluation of a communication skills training to facilitate addressing palliative care related topics in advanced cancer patients: study protocol of a multicenter randomized controlled trial (PALLI-KOM). <i>BMC Palliative Care</i> , 2020, 19, 67.	1.8	3
154	Impact of geography on prognostic outcomes of 21,509 patients with metastatic colorectal cancer enrolled in clinical trials: an ARCAD database analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110205.	3.2	3
155	Gender-specific problems and needs of family caregivers during specialist inpatient palliative care: a qualitative study on experiences of family caregivers and healthcare professionals. <i>Annals of Palliative Medicine</i> , 2021, 10, 8571-8583.	1.2	3
156	Perceived Positive and Negative Life Changes in Testicular Cancer Survivors. <i>Medicina (Lithuania)</i> , 2021, 57, 993.	2.0	3
157	Blockade of Mer By the Small Molecule Inhibitor R992 Inhibits Multiple Myeloma and Its Associated Bone Disease By Restoring the Perturbed Bone Homeostasis. <i>Blood</i> , 2018, 132, 1922-1922.	1.4	3
158	Selinexor, ARA-C and Idarubicin: An Effective and Tolerable Combination in Patients with Relapsed/Refractory AML: A Multicenter Phase II Study. <i>Blood</i> , 2015, 126, 3789-3789.	1.4	3
159	Clinical efficacy and safety of regorafenib (REG) in the treatment of metastatic colorectal cancer (mCRC) in daily practice in Germany: Interim results of the prospective multicentre noninterventional RECORA study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 769-769.	1.6	3
160	Multi-omic based molecular profiling of advanced cancer identifies treatable targets and improves survival in individual patients. <i>Oncotarget</i> , 2018, 9, 34794-34809.	1.8	3
161	Metastatic Colorectal Cancer Outcomes by Age Among ARCAD First- and Second-Line Clinical Trials. <i>JNCI Cancer Spectrum</i> , 2022, 6, .	2.9	3
162	Completion of FLOT Therapy, Regardless of Tumor Regression, Significantly Improves Overall Survival in Patients with Esophageal Adenocarcinoma. <i>Cancers</i> , 2022, 14, 1084.	3.7	3

#	ARTICLE	IF	CITATIONS
163	Indirect Treatment Comparison of Larotrectinib versus Entrectinib in Treating Patients with TRK Gene Fusion Cancers. <i>Cancers</i> , 2022, 14, 1793.	3.7	3
164	MALT1 sequencing analyses in marginal zone B-cell lymphomas reveal mutations in the translocated MALT1 allele in an IGH-MALT1-positive MALT lymphoma. <i>Leukemia and Lymphoma</i> , 2017, 58, 2480-2484.	1.3	2
165	Assessing palliative care need in left ventricular assist device patients and heart transplant recipients. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2020, 31, 874-880.	1.1	2
166	Evaluation of lesion-based response at 12 weeks (LBR12) of treatment (Rx) in metastatic colorectal cancer (mCRC): Findings from 9,092 patients (pts) in the ARCAD database.. <i>Journal of Clinical Oncology</i> , 2018, 36, 612-612.	1.6	2
167	Paclitaxel/carboplatin with or without cetuximab for treatment of carcinoma with unknown primary (PACET-CUP): Results of a multi-center randomized phase II AIO trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4120-4120.	1.6	2
168	Multicenter randomized controlled phase III study of nivolumab alone or in combination with ipilimumab as immunotherapy vs standard follow-up in surgical resectable HNSCC after adjuvant therapy.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS6095-TPS6095.	1.6	2
169	Prognostic and predictive impact of primary tumor sidedness in first-line trials for advanced colorectal cancer: An analysis of 7,828 patients in the ARCAD database.. <i>Journal of Clinical Oncology</i> , 2020, 38, 188-188.	1.6	2
170	Development of a Short Instrument for Measuring Health-Related Quality of Life in Oncological Patients for Clinical Use: Protocol for an Observational Study. <i>JMIR Research Protocols</i> , 2020, 9, e17854.	1.0	2
171	Acceptance and Benefits of Two Different Strategies to Timely Integrate Specialist Palliative Care into Routine Cancer Care: A Randomized Pilot Study. <i>Oncology Research and Treatment</i> , 2022, 45, 118-129.	1.2	2
172	Efficacy of Tigecycline as Salvage Therapy in Multidrug-Resistant Febrile Neutropenia in Patients with Acute Leukemia—A Single Center Analysis. <i>Antibiotics</i> , 2022, 11, 128.	3.7	2
173	Peritoneal carcinosis in male germ cell tumor patients: a registry study compiled by the German Testicular Cancer Study Group (GTCSG). <i>World Journal of Urology</i> , 2022, 40, 355-361.	2.2	2
174	What are the personal last wishes of people with a life-limiting illness? Findings from a longitudinal observational study in specialist palliative care. <i>BMC Palliative Care</i> , 2022, 21, 38.	1.8	2
175	RANKL regulates testicular cancer growth and Denosumab treatment has suppressive effects on GCNIS and advanced seminoma. <i>British Journal of Cancer</i> , 2022, 127, 408-421.	6.4	2
176	Retrospective analysis of three induction chemotherapy regimens in acute myeloid leukemia including CPX-351, cytarabine/daunorubicin with and without the addition of cladribine. <i>Leukemia and Lymphoma</i> , 2022, 63, 2645-2651.	1.3	2
177	Fulminant blast crisis with de novo 11q23 rearrangement in a Philadelphia-positive CML patient undergoing treatment with dasatinib. <i>Tumori</i> , 2019, 105, NP8-NP11.	1.1	1
178	Individual specialist physical activity assessment and intervention in advanced cancer patients on a palliative care ward; the 3STEPS-study. <i>Annals of Palliative Medicine</i> , 2020, 9, 4315-4322.	1.2	1
179	Tipping point: When patients stop eating and drinking in the last phase of their life. <i>Clinical Nutrition ESPEN</i> , 2020, 38, 280-282.	1.2	1
180	Salvage chemotherapy with cisplatin, ifosfamide, and paclitaxel in metastatic castration-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 123-123.	1.6	1

#	ARTICLE	IF	CITATIONS
181	Molecular- and cytogenetic characterization of the IGH associated t(1;14) in a nodal marginal zone B-cell lymphoma case. <i>Leukemia and Lymphoma</i> , 2021, , 1-5.	1.3	1
182	Expression of Cancer-Testis Antigens MAGE-C1/CT7 and MAGE-A3 Is Central to the Survival of Myeloma Cells and Their Resistance to Chemotherapy. <i>Blood</i> , 2008, 112, 3668-3668.	1.4	1
183	A single arm, open-label multicenter phase II trial of everolimus in patients with relapsed/refractory germ cell cancer (RADIT).. <i>Journal of Clinical Oncology</i> , 2014, 32, e15535-e15535.	1.6	1
184	How to improve toxicity evaluation in clinical trials? Testing new metrics from irinotecan or oxaliplatin-based treatments in metastatic colorectal cancer (mCRC): A pooled analysis from 2,349 patients in ARCAD database.. <i>Journal of Clinical Oncology</i> , 2020, 38, 89-89.	1.6	1
185	BGB324 Represents an Axl and BCR-ABL1 Inhibitor with Activity in the T315I Mutant. <i>Blood</i> , 2014, 124, 4512-4512.	1.4	1
186	Effects of a structured intervention program to improve physical activity (PA) of adolescents and young adult cancer survivors (AYAs): Final results of the randomized Motivate AYAâ€™MAYA trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 11518-11518.	1.6	1
187	Evaluation of an electronic psycho-oncological adaptive screening program (EPAS) with immediate patient feedback: findings from a German cluster intervention study. <i>Journal of Cancer Survivorship</i> , 2021, , 1.	2.9	1
188	First-line salvage treatment options for germ cell tumor patients failing stage-adapted primary treatment. <i>World Journal of Urology</i> , 2022, , 1.	2.2	1
189	Approaches of stem cell mobilization in a large cohort of metastatic germ cell cancer patients. <i>Bone Marrow Transplantation</i> , 2022, , .	2.4	1
190	Donorâ€™transmitted extramedullary acute myeloid leukaemia after living donor kidney transplantation. <i>British Journal of Haematology</i> , 2022, , .	2.5	1
191	Diagnostic Utility of Bronchoalveolar Lavage in Patients with Acute Leukemia under Broad-Spectrum Anti-Infective Treatment. <i>Cancers</i> , 2022, 14, 2773.	3.7	1
192	Abstract 3374: Large-scale single-cell whole transcriptomic analyses reveal distinct malignant phenotypes of CTCs from NSCLC patients. <i>Cancer Research</i> , 2022, 82, 3374-3374.	0.9	1
193	Response to epithelial growth factor receptor inhibitor (EGFRi) treatment in patients with early-onset, treatment-naïve metastatic colorectal cancer (mCRC): An ARCAD database analysis.. <i>Journal of Clinical Oncology</i> , 2022, 40, 3572-3572.	1.6	1
194	Cancer Cells Expressing Oncogenic Rat Sarcoma Show Drug-Addiction Toward Epidermal Growth Factor Receptor Antibodies Mediated by Sustained MAPK Signaling. <i>Frontiers in Oncology</i> , 2020, 9, 1559.	2.8	0
195	In vitro and in vivo investigations of novel 1,4-napthoquinone sulphomethylene carbohydrate conjugates in prostate cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 104-104.	1.6	0
196	Evaluating longitudinal toxicity of cetuximab in patients with metastatic colorectal cancer (mCRC): A pooled analysis from 1,302 patients in the ARCAD database.. <i>Journal of Clinical Oncology</i> , 2021, 39, 3610-3610.	1.6	0
197	No Adverse Impact of 13q14 and P53 Deletion, t(4;14)(p16;q32) or Overrepresentation of CMYC(8q24) as Detected by Fluorescence In Situ Hybridization on Outcome in Patients with Multiple Myeloma Following Dose-Reduced Allogeneic Stem Cell Transplantation.. <i>Blood</i> , 2006, 108, 5038-5038.	1.4	0
198	Identification of Circulating Lymphendothelial Cells in the Blood of Patients with Solid Tumors.. <i>Blood</i> , 2006, 108, 3947-3947.	1.4	0

#	ARTICLE	IF	CITATIONS
199	Cilengitide Inhibits Proliferation and Differentiation of Human Endothelial Progenitor Cells In Vitro.. Blood, 2006, 108, 3929-3929.	1.4	0
200	Multiple Myeloma Patients Treated with Allogeneic Stem Cell Transplantation Show an Increased Frequency of Bone Marrow-Residing CD4+Foxp3+ T Regulatory Cells.. Blood, 2006, 108, 5206-5206.	1.4	0
201	The clonality of immunoglobulin repertoire in prostate cancer-infiltrating B cells.. Journal of Clinical Oncology, 2012, 30, e15168-e15168.	1.6	0
202	Prognostic factors for the efficacy of catumaxomab in patients (pts) with malignant ascites (MA): Meta-analysis from two phase III studies.. Journal of Clinical Oncology, 2013, 31, 3078-3078.	1.6	0
203	Molecular profiling of testicular cancer.. Journal of Clinical Oncology, 2014, 32, 4515-4515.	1.6	0
204	Calculators for overall survival (OS) and progression-free survival (PFS) in metastatic colorectal cancer (mCRC): Construction from 19,678 ARCAD patients.. Journal of Clinical Oncology, 2015, 33, 3555-3555.	1.6	0
205	Efficacy and safety of gemcitabine, oxaliplatin and paclitaxel (GOP) in cisplatin-refractory germ cell tumors in routine care: Registry data from an outcomes research project.. Journal of Clinical Oncology, 2015, 33, e15570-e15570.	1.6	0
206	Epidermal growth factor receptor mutations may confer resistance or cross-resistance to cetuximab and panitumumab and can be detected in circulating tumor DNA.. Journal of Clinical Oncology, 2015, 33, 3549-3549.	1.6	0
207	BGB324 Inhibits BCR-ABL TKI-Resistant Chronic Myeloid Leukemia. Blood, 2015, 126, 1569-1569.	1.4	0
208	Improved Nutrition in Adolescents and Young Adults after childhood cancer: INAYAâ€”A pilot study.. Journal of Clinical Oncology, 2016, 34, 173-173.	1.6	0
209	Large retroperitoneal lymphadenopathy (RPLN) and increased risk of venous thromboembolism (VTE) in patients (pts) with metastatic germ cell tumours (mGCT): A Global Germ Cell Cancer Group (G3) Study.. Journal of Clinical Oncology, 2016, 34, e16058-e16058.	1.6	0
210	Associations of incidence of common adverse events (AEs) and survival outcomes in metastatic colorectal cancer (mCRC) patients (pts) treated with first line chemotherapy: Findings from 9,812 pts in the ARCAD database.. Journal of Clinical Oncology, 2018, 36, 617-617.	1.6	0
211	Evaluating gender as a predictive marker for response to bevacizumab (Bev) in metastatic colorectal carcinoma (mCRC): Pooled analysis of 3369 patients (pts) in the ARCAD database.. Journal of Clinical Oncology, 2019, 37, 3539-3539.	1.6	0
212	Treatment effects (TEs) of EGFR monoclonal antibodies (mAbs) in metastatic colorectal cancer (mCRC) patients (pts) with KRAS, NRAS, and BRAF mutation (MT) status: Individual patient data (IPD) meta-analysis of randomized trials from the ARCAD database.. Journal of Clinical Oncology, 2020, 38, 4090-4090.	1.6	0
213	Integrative public data-mining pipeline for the validation of novel independent prognostic biomarkers for lung adenocarcinoma. Biomarkers in Medicine, 2020, 14, 1651-1662.	1.4	0
214	Benefit of prophylactic anticoagulation before and during first-line chemotherapy on patients with metastatic germ cell tumors.. Journal of Clinical Oncology, 2020, 38, 402-402.	1.6	0
215	Increased Frequency of TOX+ CD39+ TIGIT+ CD73- CD8+ T Cells in Patients with Newly Diagnosed AML. Blood, 2020, 136, 36-36.	1.4	0
216	Surgical Site Cytology to Diagnose Spinal Lesions. Diagnostics, 2022, 12, 310.	2.6	0

#	ARTICLE	IF	CITATIONS
217	Trajectories of body weight change and survival among mCRC patients treated with systemic therapy: Pooled analysis from the ARCAD database.. Journal of Clinical Oncology, 2022, 40, 80-80.	1.6	0
218	Overall survival (OS) of patients with TRK fusion-“positive cancer receiving larotrectinib versus standard of care (SoC): A matching-adjusted indirect comparison (MAIC) using real-world data (RWD).. Journal of Clinical Oncology, 2022, 40, 6579-6579.	1.6	0
219	First-line (L1) therapy targeting EGFR in lung metastases (mets) of colorectal cancer (mCRC): An ARCAD pooled analysis.. Journal of Clinical Oncology, 2022, 40, 3578-3578.	1.6	0